APTITUDE HEALTH®

EPICS

Conference Coverage: EHA 2022 – Focus on Lymphoma

June 16, 2022

Report Contents

EPICS

Content	Slide
Meeting Snapshot	3
Faculty Panel	4
Meeting Agenda	5
Key Insights and Strategic Recommendations	6
Congress Highlights	8
Key Insights	31

Meeting Snapshot

EPICS

EPICS

VIRTUAL CLOSED-DOOR ROUNDTABLE

DATE:
June 16, 2022



DISEASE STATE AND DATA PRESENTATIONS by key experts

INSIGHTS REPORT including postmeeting analyses and actionable recommendations

PANEL: Key experts in lymphoma
> 4 from US
> 4 from Europe

LYMPHOMA-SPECIFIC DISCUSSIONS on therapeutic advances and their application in clinical decision-making

Panel Consisting of 4 US and 4 European Lymphoma Experts

EPICS

Paolo Caimi, MD
Case Comprehensive Cancer Center

Stefan Barta, MD, MS, MRCPCUK
Penn Medicine

Matthew Lunning, DO, FACP
University of Nebraska Medical Center

CHAIR:
Brad Kahl, MD
Washington University School of Medicine

John Gribben, MD, DSc, FRCP, FRCPath
Cancer Research UK Barts Centre

Georg Hess, MD
Johannes Gutenberg University

Olivier Tournilhac, MD, PhD
Clermont-Ferrand University

Pier Luigi Zinzani, MD, PhD
University of Bologna Institute of Hematology and Medical Oncology

APTITUDE HEALTH®

Meeting Agenda

EPICS

Time (EST/CEST)	Topic	Speaker/Moderator
9.00 AM – 9.05 AM/15.00 – 15.05	**Welcome and Introductions**	Brad Kahl, MD
9.05 AM – 9.15 AM/15.05 – 15.15	**Advances in DLBCL/Aggressive B-Cell Lymphoma**	Matthew Lunning, DO, FACP
9.15 AM – 9.40 AM/15.15 – 15.40	Discussion and Key Takeaways	All
9.40 AM – 9.45 AM/15.40 – 15.45	**Updates on T-Cell Lymphoma**	Stefan K. Barta, MD, MS, MRCPCUK
9.45 AM – 10.00 AM/15.45 – 16.00	Discussion and Key Takeaways	All
10.00 AM – 10.05 AM/16.00 – 16.05	**Advances in FL**	Paolo Caimi, MD
10.05 AM – 10.10 AM/16.05 – 16.10	**Advances in MCL**	Georg Hess, MD
10.10 AM – 10.15 AM/16.10 – 16.15	**Advances in MZL/Waldenström Macroglobulinemia**	Pier Luigi Zinzani, MD, PhD
10.15 AM – 10.50 AM/16.15 – 16.50	Discussion and Key Takeaways	All
10.50 AM – 11.00 AM/16.50 – 17.00	**BREAK**	
11.00 AM – 11.10 AM/17.00 – 17.10	**Evolving Therapies in CLL/SLL**	Olivier Tournilhac, MD, PhD
11.10 AM – 11.30 AM/17.10 – 17.30	Discussion and Key Takeaways	All
11.30 AM – 11.40 AM/17.30 – 17.40	**Role of Fixed-Duration and MRD-Guided Strategies in CLL**	John Gribben, MD, DSc, FRCP
11.40 AM – 11.55 AM/17.40 – 17.55	Discussion and Key Takeaways	All
11.55 AM – 12.00 PM/17.55 – 18.00	**Summary and Closing Remarks**	Brad Kahl, MD

APTITUDE HEALTH®

EPICS

Congress Highlights

Glofitamab in patients with R/R DLBCL: Pivotal phase II expansion results and analysis of immune correlates

Dickinson M, et al. 2022, EHA S220; Piccione E, et al. 2022, EHA P1210

EPICS

STUDY POPULATION

> Pts with DLBCL and at least 2 prior therapies

Duration of CR

Subcutaneous epcoritamab + R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma: Phase 1/2 update

Clausen M, et al. 2022, EHA P1214

EPICS

STUDY POPULATION

> Pts with newly diagnosed DLBCL and IPI ≥3

Response Profile

Zanubrutinib combined with R-CHOP in the treatment of newly diagnosed non-GCB DLBCL with extranodal involvement: A prospective phase II study

EPICS

Li C, et al. 2022, EHA P1185

STUDY POPULATION

> Pts with newly diagnosed, non-GCB DLBCL with extranodal

Efficacy and Survival of Patients Completing Treatment

Zanubrutinib, lenalidomide plus R-CHOP (ZR^2-CHOP) as the first-line treatment for non-GCB DLBCL

Zhu H, et al. 2022, EHA P1219

EPICS

STUDY POPULATION

- Pts with high-risk, non-GCB DLBCL and no prior therapy

ctDNA Clearance in a Patient With a *TP53* Mutation

Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma

McMillan A, et al. 2022, EHA P1189

EPICS

STUDY POPULATION

Peripheral Neuropathy With Pola–R-GemOx

A phase I/II study of golidocitinib, a selective JAK1 inhibitor, in refractory or relapsed peripheral T cell lymphoma

Kim W, et al. 2022, EHA S218

EPICS

STUDY POPULATION

> Pts with R/R PTCL

Reduction in Tumor Burden

Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma from the phase 2 PRIMO trial: Updated expansion phase analysis

Zinzani P, et al. 2022, EHA P1172

EPICS

STUDY POPULATION

> Pts with R/R PTCL

Reduction in Tumor Burden

Tislelizumab, a PD-1 inhibitor, for relapsed/refractory mature T- and NK-cell neoplasms: Results from a phase 2 study

Bachy E, et al. 2022, EHA P1239

EPICS

STUDY POPULATION

- Pts with R/R ENKTL, PTCL, or CTCL

DOR in PTCL-NOS

Preliminary analysis of the phase II study using tolinapant (ASTX660) monotherapy in 98 PTCL and 51 CTCL subjects with R/R disease

Michot J, et al. 2022, EHA S217

EPICS

STUDY POPULATION

- Pts with R/R PTCL or CTCL and at least 2 prior systemic

Responses in Patients With PTCL

Zanubrutinib + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma: Primary analysis of the phase 2 randomized ROSEWOOD trial

EPICS

Zinzani P, et al. 2022, EHA S205

STUDY POPULATION

> Pts with R/R FL and at least 2 prior systemic therapies, including

Overall Survival

Obinutuzumab plus chemotherapy demonstrates long-term benefit over rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: Final analysis of the GALLIUM study

Townsend W, et al. 2022, EHA S206

EPICS

STUDY POPULATION

> Pts with previously untreated FL

PFS per Investigators (primary endpoint)

Primary results from the phase 3 SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle-cell lymphoma

Wang M, et al. 2022, EHA S209

EPICS

STUDY POPULATION

> Pts with previously untreated MCL

PFS (primary endpoint)



Acalabrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): Results of a phase 2, multicenter, open-label trial

Strati P, et al. 2022, EHA P1129

EPICS

STUDY POPULATION

> Pts with MZL and at least 1 prior therapy, including 1 anti-CD20

Reduction in Tumor Burden



Zanubrutinib in older patients with relapsed/refractory marginal zone lymphoma: Subgroup analysis of the MAGNOLIA study

Opat S, et al. 2022, EHA P1162

EPICS

STUDY POPULATION

> Pts with R/R MZL and at least 1 CD20-directed regimen

Reduction in Tumor Burden

ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia

Dimopoulos M, et al. 2022, EHA P1161

EPICS

STUDY POPULATION

> Pts with WM requiring therapy

Responses Over Time in *MYD88*^{MUT} (primary endpoint)

Long term outcomes of IFCG regimen for first line treatment of patients with CLL with mutated IGHV and without del(17P)/TP53 mutation

Jain N, et al. 2022, EHA S149

EPICS

STUDY POPULATION

- Pts with previously untreated CLL and mutated *IGHV*; no del(17p)

PFS and OS

Patient-reported outcomes from a phase 3 randomized study of zanubrutinib versus bendamustine plus rituximab in patients with treatment-naïve CLL/SLL

Ghia P, et al. 2022, EHA P662

EPICS

STUDY POPULATION

> Pts with treatment-naive CLL/SLL (SEQUOIA trial)

Improvement in QOL at Week 24

Acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil in treatment-naive chronic lymphocytic leukemia: 5-year follow-up of ELEVATE-TN

Sharman J, et al. 2022, EHA P666

EPICS

STUDY POPULATION

> Pts with treatment-naive CLL

PFS per Investigators

Acalabrutinib vs rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at ~4 years of follow-up

Ghia P, et al. 2022, EHA P668

EPICS

STUDY POPULATION

> Pts with R/R CLL

PFS (primary endpoint)

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 5-year results of the randomized CLL14 study

Al-Sawaf O, et al. 2022, EHA S148

EPICS

STUDY POPULATION

> Pts with previously untreated CLL and coexisting medical

PFS (primary endpoint)

The combination of ibrutinib plus venetoclax results in a high rate of MRD negativity in previously untreated CLL: The results of the planned interim analysis of the phase III NCRI FLAIR trial

Hillmen P, et al. 2022, EHA S145

EPICS

STUDY POPULATION

> Pts with previously untreated CLL requiring therapy

MRD Negativity at 2 Years



Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma: 3-year follow-up from the phase 2 CAPTIVATE study FD cohort

Moreno C, et al. 2022, EHA P669

EPICS

STUDY POPULATION

> Pts with previously untreated CLL/SLL requiring therapy

Best Response to Ibrutinib-Venetoclax

APTITUDE HEALTH®

EPICS

Key Insights

Advances in DLBCL/Aggressive B-Cell Lymphoma (1/2)

EPICS

Expert opinion is that the most impactful data in DLBCL at EHA 2022 came from trials of bispecific antibodies and next-generation BTK inhibitors

> Epcoritamab + R-CHOP in first-line, high-risk DLBCL (#P1214)

Advances in DLBCL/Aggressive B-Cell Lymphoma (2/2)

EPICS

- Glofitamab in relapsed/refractory DLBCL (#S220)
  - These data are seen by the experts as impressive and good enough for approval as a single agent

Updates on T-Cell Lymphoma

EPICS

The experts are enthusiastic about the number of new classes of agents for patients with T-cell lymphoma (TCL)

> One of the experts pointed out that the previous generation of agents approved for relapsed/refractory TCL had response rates of ~30%; in

Advances in FL, MCL, MZL, WM (1/2)

EPICS

Follicular Lymphoma (FL)

> The experts think the ROSEWOOD trial of zanubrutinib-obinutuzumab vs obinutuzumab in relapsed/refractory FL was unexpectedly positive,

Advances in FL, MCL, MZL, WM (2/2)

EPICS

Mantle Cell Lymphoma (MCL)

> Expert opinion is that the SHINE study adding ibrutinib or placebo to BR and rituximab maintenance in patients with previously untreated MCL

Evolving Therapies in CLL/SLL

EPICS

Expert opinion is that for patients with CLL and mutated *IGHV*, approaches with chemotherapy such as IFCG (ibrutinib, fludarabine,

Role of Fixed-Duration and MRD-Guided Strategies in CLL

EPICS

Expert opinion is that fixed-duration combination regimens will play a part in the treatment of CLL patients, although it may be possible